The acquisition expands Lilly’s immunology pipeline with lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 that is being evaluated for moderate-to-severe atopic dermatitis in adolescents and adults.
Eli Lilly and Company has completed its acquisition of Dermira, Inc.
The acquisition expands Lilly’s immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older.
The acquisition of Dermira also expands Lilly’s portfolio of marketed dermatology medicines with the addition of QBREXZ (glycopyrronium), a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis.
“We are pleased to complete the acquisition of Dermira, and look forward to continuing their important work to develop new therapeutic options for patients with chronic skin conditions,” says Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines, in a news release.
Lilly’s tender offer for all outstanding shares of common stock of Dermira, at a price of $18.75 per share in cash, expired as scheduled at one minute past 11:59 PM ET on February 19, 2020. As of the expiration of the tender offer, 40,926,025 shares of Dermira common stock were validly tendered and not properly withdrawn, representing approximately 74.8 percent of the shares of Dermira common stock outstanding, and have been accepted for payment under the terms of the tender offer. Following completion of the tender offer, Lilly completed the acquisition of Dermira through the previously planned second-step merger. Dermira’s common stock will be delisted from the NASDAQ Stock Market.
